Ascletis Partners with Simcere for Ritonavir Supply in COVID-19 Drug Development
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co.,...
HKG: 1672
Ascletis Pharma Initiates Dosing in Phase I Trial for COVID-19 Treatment ASC11
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the dosing of four healthy subjects in...
Viking Therapeutics Sues Ascletis Pharma Over Alleged Trade Secret Theft
US – based Viking Therapeutics (NASDAQ: VKTX) is set to take China’s Ascletis Pharma Inc....
Ascletis Pharma Receives USPTO Notice for ASC10 Patent
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the Notice of Issuance from the...
Ascletis Pharma Announces Positive Phase I Results for ASC10 in COVID-19 Treatment
China-based Ascletis Pharma Inc., (HKG: 1672) announced the positive topline results from its Phase I...
CSPC and Ascletis Get NMPA Approval for COVID-19 Drug Clinical Trials
China-based firms CSPC Pharmaceutical Group Ltd (HKG: 1093) and Ascletis Pharma Inc. (HKG: 1672) both...
Ascletis Pharma Completes Enrollment for ASC40 Phase II Acne Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced the completion of enrollment of 180 patients in...
Ascletis Pharma’s COVID-19 Drug Candidate ASC11 Accepted for Review by NMPA
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that its Investigational New Drug (IND) filing...
Ascletis Pharma’s PD-L1 Inhibitor ASC61 Gains NMPA IND Approval
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the approval of the Investigational New Drug...
Ascletis Pharma Presents Phase I Study Results for ASC43F at AASLD
China-based Ascletis Pharma Inc. (HKG: 1672) made a poster presentation detailing the abstract of a...
Ascletis Files IND Application for COVID-19 Oral Inhibitor ASC11 with FDA
China-based Ascletis Pharma Inc. (HKG: 1672) has announced that the Investigational New Drug (IND) application...
Ascletis Signs Pact with Pfizer China for Ritonavir Tablets
Ascletis Pharma Inc. (HKG: 1672) announced that its wholly-owned subsidiary Ascletis Pharmaceuticals Co., Ltd has...
Ascletis Pharma Files IND for Monkeypox Antiviral ASC10 with FDA
China-based Ascletis Pharma Inc. (HKG: 1672) announced the submission of an Investigational New Drug (IND)...
Ascletis Pharma Doses First Patient in Phase II Study of ASC41 for NASH
Ascletis Pharma Inc. (HKG: 1672), a China-based biopharmaceutical company, has announced that the first patient...
Ascletis Pharma and Roche Terminate Promotion Agreement for Pegasys
China-based Ascletis Pharma Inc. (HKG: 1672) has announced a supplementary agreement with Swiss pharmaceutical giant...
Ascletis Completes Enrollment for HIV Functional Cure Study with PD-L1 Antibody ASC22
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the clinical study of PD-L1 antibody ASC22...
Ascletis Pharma’s H1 2022 Revenue Rises 4.8% on R&D and Product Sales Growth
Ascletis Pharma Inc. (HKG: 1672) reported RMB 38.2 million (USD 5.96 million) in revenue for...
Ascletis Pharma’s Gannex Initiates DDI Study for ASC42 in PBC
Ascletis Pharma Inc. (HKG: 1672) announced that its wholly – owned US unit, Gannex, has...
Ascletis Pharma’s ASC10 Receives IND Approval for COVID-19 Treatment in US and China
China-based Ascletis Pharma Inc. (HKG: 1672) has provided updates on the clinical progress of ASC10,...
Ascletis Pharma Files IND Application for ASC10 with US FDA
China-based Ascletis Pharma Inc. (HKG: 1672) announced that it has filed an Investigational New Drug...